What is Medical Developments International OCF Yield %?
Medical Developments InternationalFRA:M5D +1.55%32 OCF Yield % is 2.12 as of Jun. 26, 2026, which is 5200% above its 10-year median of 0.04. GuruFocus rates FRA:M5D with a GF Score™ of 32/100 and a GF Value™ of €0.35 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Medical Developments International ranks worse than 58.31% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Medical Developments International OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Medical Developments International OCF Yield % Related Terms
Medical Developments International OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International OCF Yield % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Medical Developments International's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International (FRA:M5D) has a OCF Yield % of 2.12 as of Jun. 26, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Medical Developments International and its competitors. This is 5200% above median its historical median of 0.04. According to the industry distribution chart, Medical Developments International ranks #586 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 58.3%.
Is Medical Developments International's OCF Yield % too high?
Medical Developments International's current OCF Yield % of 2.12 is 5200% above median its 10-year median of 0.04. The Drug Manufacturers industry median OCF Yield % is 3.61. Medical Developments International's value of 2.12 is 41.3% below this industry median. Based on the distribution chart, Medical Developments International ranks #586 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medical Developments International has a GF Score™ of 32/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's OCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #586 out of 1005 companies for OCF Yield %. This places Medical Developments International in the lower half of its industry. The industry median OCF Yield % is 3.61. Medical Developments International's value of 2.12 is 41.3% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 3.61, Medical Developments International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current OCF Yield % of 2.12 is 41.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current OCF Yield % is 2.12, which is 5200% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (FRA:M5D) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.35, compared to a current price of €0.20 — trading 43.7% below its estimated fair value. The current OCF Yield % is 2.12, which is 5200% above median its 10-year median of 0.04 and 41.3% below the Drug Manufacturers industry median of 3.61. Medical Developments International's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Medical Developments International (FRA:M5D), the current OCF Yield % is 2.12 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (FRA:M5D) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of €0.20 is trading 43.7% below its estimated GF Value™ of €0.35.
GuruFocus considers Medical Developments International to be Significantly Undervalued.
Key valuation signals for FRA:M5D:
OCF Yield %: 2.12 (5200% above median its 10-year median of 0.04)
GF Value™: €0.35 vs. price of €0.20 (43.7% below fair value)
Industry Position: 41.3% below the Drug Manufacturers median (#586 of 1005)
No single metric tells the full story. See the FRA:M5D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Business Description
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
32GF Score
Get the complete analysis for FRA:M5D
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M5D has been successfully added to your 
